Medindia

X

New Drug Holds Promise For Myeloma Treatment

by Tanya Thomas on  June 9, 2010 at 10:48 AM Cancer News   - G J E 4
A new weapon in the artillery against myeloma is Elotuzumab, a drug originally designed to target cancerous plasma cells. It has now also been found promising in the treatment of myeloma, a type of blood cancer.
 New Drug Holds Promise For Myeloma Treatment
New Drug Holds Promise For Myeloma Treatment
Advertisement

A study looked at elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism. The early stage trial combined elotuzumab with bortezomib, or Velcade, one of the novel chemotherapies approved to treat multiple myeloma, a cancer that arises in the plasma cells.

Advertisement
"Elotuzumab was found to work in synergy with bortezomib in a pre-clinical model, which served as the basis for this clinic trial. The regimen was well-tolerated, and many patients stayed on it for a long time," says Andrzej Jakubowiak, M.D., Ph.D., director of the Multiple Myeloma Program at the University of Michigan Comprehensive Cancer Center.

The study was presented at the American Society of Clinical Oncology annual meeting.

The study looked at 28 patients with multiple myeloma that had relapsed or become unresponsive to treatment. Overall, 48 percent responded to the elotuzumab and bortezomib combination and patients' cancer progressed after an average 9.45 months. These numbers are better than in previous studies of patients with less advanced disease treated with bortezomib alone in which 38 percent responded to the treatment and cancer progressed after an average of 6.22 months.

"The study was not designed to evaluate statistical superiority of the combination of elotuzumab and Velcade, but it does appear to support our preclinical evidence that these two drugs work together," Jakubowiak says.

The researchers will next consider a study to compare the combination of elotuzumab and bortezomib against standard therapy to see if the combination achieves better results.

Source: ANI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All